Institute of Bioengineering and Bioimaging (IBB)

Safe for human cells but toxic to bacteria, fungi and viruses, a new strategy for sanitising surfaces could give us the advantage in the fight against pathogens.

A new microfluidic liver-on-a-chip platform offers drug developers a stable, scalable and sensitive testing ground for much-needed treatments in fatty liver disease.

Researchers develop machine learning models for accurately diagnosing an inflammatory skin condition.

A new diagnostic innovation powered by artificial intelligence could empower surgeons to make more accurate and effective clinical decisions for colon cancer patients.

Imaging experts discover a non-invasive method to identify which patients with liver cancer are most likely to respond to immunotherapy.

Game-changing new ideas and products are born from connecting the right minds and hands. In this cover story, we spotlight how A*STAR facilitates those connections and cultivates the culture needed for an ecosystem of innovation.

Non-invasive imaging technology reveals how radiation exposure in the brain, particularly early in life, damages delicate brain tissue.

A head-to-head test of three common mask decontamination methods helps frame standardised national guidelines.

New self-cleaning surfaces created by A*STAR researchers take inspiration from cicada wings to attract and destroy microbes without harsh chemicals.

Synthetic DNA molecules could serve as an easy-to-manufacture alternative to traditional antibody-based rapid tests.

A*STAR scientists develop an optoacoustic imaging technology for diagnosing disease by assessing subtle blood flow changes in the skin.

By identifying the best way to decontaminate N95 masks, A*STAR scientists are helping solve the environmental consequences of disposable masks.